Literature DB >> 4521089

Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans.

S H Wan, D H Huffman, D L Azarnoff, B Hoogstraten, W E Larsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4521089

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  14 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

Review 2.  Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge.

Authors:  Karin Holweger; Carsten Bokemeyer; Hans-Peter Lipp
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 3.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.

Authors:  John F DiPersio; Harry P Erba; Richard A Larson; Selina M Luger; Martin S Tallman; Jeffrey M Brill; Gregoire Vuagniaux; Elisabeth Rouits; J Mel Sorensen; Claudio Zanna
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-03-05

Review 5.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil.

Authors:  B Chandrasekaran; T E Kute; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.

Authors:  A L Harris; C Potter; C Bunch; J Boutagy; D J Harvey; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

8.  Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.

Authors:  Mohamed Elmeliegy; Jason Den Haese; Chetasi Talati; Meir Wetzler; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2020-08-03       Impact factor: 3.333

Review 9.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

10.  AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Authors:  L H Lindner; H Ostermann; W Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.